The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | N | Nervous system | |
2 | N07 | Other nervous system drugs | |
3 | N07C | Antivertigo preparations | |
4 | N07CA | Antivertigo preparations |
Code | Title | |
---|---|---|
N07CA01 | Betahistine | |
N07CA02 | Cinnarizine | |
N07CA03 | Flunarizine | |
N07CA04 | Acetylleucine | |
N07CA52 | Cinnarizine, combinations |
Active Ingredient | Description | |
---|---|---|
Betahistine |
Betahistine dihydrochloride is a histamine-like drug in which pharmacological activity can be attributed to a specific effects and/or more direct influences on recovery mechanisms the vestibular nuclei. It has weak agonist activity at histamine H1 receptors and moderate antagonist activity at H3 receptors. Betahistine may increase blood flow to the cochlear region as well as to the whole brain. |
|
Cinnarizine |
Cinnarizine has been shown to be a non-competitive antagonist of the smooth muscle contractions caused by various vasoactive agents including histamine. Cinnarizine also acts on vascular smooth muscle by selectively inhibiting the calcium influx into depolarised cells, thereby reducing the availability of free Ca2+ ions for the induction and maintenance of contraction. |
|
Flunarizine |
Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy. |
Title | Information Source | Document Type | |
---|---|---|---|
ALFINOR Tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
BETA-SYNTO Tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
CINNARON Hard capsule | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
CINNARON Tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
SERC Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
SIBELIUM Tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
STUGERON Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
TREVIGO Tablet | Marketing Authorisation Holder | MPI, Generic | |
VERTIMED Tablet | MPI, EU: SmPC |